Report overview
The global Candida Infections Drugs market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Azole Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Candida Infections Drugs include F. Hoffmann-La Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK plc, Novartis AG, AstraZeneca and Johnson & Johnson Private Limited, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Candida infection is a yeast infection where the skin acts as a host organism, and the infection multiplies and grows with the period. Candida albicans are the most common species of this infection. Candida normally lives on the skin and inside the body, such as the throat, gut, mouth, and vagina, without causing problems. It can cause infections if it grows out of control or enters deep into the body.
This report aims to provide a comprehensive presentation of the global market for Candida Infections Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Candida Infections Drugs. This report contains market size and forecasts of Candida Infections Drugs in global, including the following market information:
Global Candida Infections Drugs Market Revenue, 2020-2024, 2025-2030, ($ millions)
Global Candida Infections Drugs Market Sales, 2020-2024, 2025-2030, (K Units)
Global top five Candida Infections Drugs companies in 2023 (%)
We surveyed the Candida Infections Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Candida Infections Drugs Market, by Type, 2020-2024, 2025-2030 ($ Millions) & (K Units)
Global Candida Infections Drugs Market Segment Percentages, by Type, 2023 (%)
Azole
Nystatin
Other
Global Candida Infections Drugs Market, by Application, 2020-2024, 2025-2030 ($ Millions) & (K Units)
Global Candida Infections Drugs Market Segment Percentages, by Application, 2023 (%)
Beriberi
Jock Itch
Vaginal Infection
Other
Global Candida Infections Drugs Market, By Region and Country, 2020-2024, 2025-2030 ($ Millions) & (K Units)
Global Candida Infections Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Candida Infections Drugs revenues in global market, 2020-2024 (Estimated), ($ millions)
Key companies Candida Infections Drugs revenues share in global market, 2023 (%)
Key companies Candida Infections Drugs sales in global market, 2020-2024 (Estimated), (K Units)
Key companies Candida Infections Drugs sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffmann-La Roche Ltd
Mylan NV
Teva Pharmaceutical Industries Ltd
Sanofi
Pfizer Inc
GSK plc
Novartis AG
AstraZeneca
Johnson & Johnson Private Limited
Sun Pharmaceutical Industries Ltd
Merck & Co., Inc
Bristol-Myers Squibb Company
Lilly
Amgen Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Candida Infections Drugs, market overview.
Chapter 2: Global Candida Infections Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Candida Infections Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Candida Infections Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Candida Infections Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
